Related Experiment Videos
Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207
1Department of Physiology, School of Medicine, Keio University, Tokyo, Japan.
Purpose:
Surgical removal remains the only potentially curative therapy for renal cell carcinoma. In this study we evaluated the inhibitory effect of the replication competent engineered herpes simplex virus type 1, G207, for renal cell carcinoma in vitro and in vivo.
Materials And Methods:
The nature of G207 enables it to replicate within cancer cells, thus, causing cytolysis, but replication is restricted within normal cells. The susceptibility of the human renal cancer cell lines ACHN and A498 to G207 at a multiplicity of infection of 0.1 was examined. In addition, the growth characteristics of G207 was assessed. In vivo athymic mice bearing subcutaneous tumors were inoculated with 1 x 10(7) plaque forming units of G207 intra-neoplastically. For pathological analysis subcutaneous tumors were stained with X-gal.
Results:
Two cell lines were efficiently destroyed by G207 within 1 week. The viral yields of G207 increased in a time dependent manner. In vivo the intra-neoplastic inoculation of G207 caused significantly decreased tumor growth in athymic mice harboring subcutaneous human renal cancer cells. On day 14 the mean growth ratio of ACHN and A498 lesions was significantly inhibited in G207 treated compared to control tumors (p <0.005 and <0.0001, respectively).
Conclusions:
These results suggest that G207 should be considered another potential therapeutic agent for renal cell carcinoma.
Insights
The engineered herpes simplex virus type 1, G207, effectively destroyed renal cell carcinoma cells in vitro and inhibited tumor growth in vivo. G207 shows potential as a novel therapeutic agent for renal cell carcinoma.
Area of Science:
- Oncolytic virotherapy
- Genetically engineered herpes simplex virus type 1 (G207)
- Renal cell carcinoma (RCC) research
Background:
- Surgical removal is the primary curative treatment for renal cell carcinoma.
- Novel therapeutic strategies are needed to complement or replace existing treatments.
Purpose of the Study:
- To evaluate the efficacy of G207, a replication-competent engineered herpes simplex virus type 1, against renal cell carcinoma.
- To assess the in vitro and in vivo anti-cancer activity of G207.
Main Methods:
- In vitro: Human renal cancer cell lines (ACHN, A498) were infected with G207.
- In vivo: Athymic mice with subcutaneous human renal cancer xenografts were treated with intra-neoplastic G207 inoculation.
- Viral replication and tumor growth inhibition were assessed.
Main Results:
- G207 efficiently destroyed ACHN and A498 cell lines within one week.
- G207 replication increased in a time-dependent manner.
- Intra-neoplastic G207 inoculation significantly inhibited tumor growth in vivo (p <0.005 for ACHN, p <0.0001 for A498).
Conclusions:
- G207 demonstrates significant oncolytic activity against renal cell carcinoma cells in vitro.
- G207 effectively suppresses renal cell carcinoma tumor growth in a preclinical in vivo model.
- These findings support G207 as a potential therapeutic agent for renal cell carcinoma.